CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapyJohannes Sam, Pablo Umaña, Daniel Marbach et al.|Blood|2024Cited by 40
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBsOmar Abdelmotaleb, Christian Klein, Anneliese Schneider et al.|mAbs|2025Cited by 2
Abstract 1235: Impact of anti-CD3 and tumor-target binder affinities on <i>in-vitro</i> potency, <i>in-vivo</i> efficacy, and cytokine releaseOmar Abdelmotaleb, Christian Klein, Anneliese Schneider et al.|Cancer Research|2024Cited by 1
P-02.04 Developing T cell bispecific antibodies with reduced-affinity anti-CD3 binders for a potent, efficacious, and low-cytokine responseOmar Abdelmotaleb, Anina Schneider, C Klein et al.|Poster presentations|2025Cited by 0
Abstract 3416: Advancing cancer immunotherapy: PD-L1-targeted IFNa2a fusion protein RO7694744Moritz Rapp, Pablo Umaña, Harald Duerr et al.|Cancer Research|2025Cited by 0